Virginia Commonwealth University

VCU Scholars Compass
Graduate Research Posters

Graduate School

2020

Offering the Choice of Self-Administered Oral HIV Testing
(CHIVST) among Long-distance Truck Drivers in Kenya: A Trialbased Cost-effectiveness Analysis
Deo Mujwara
Virginia Commonwealth University

April D. Kimmel

Follow this and additional works at: https://scholarscompass.vcu.edu/gradposters
Part of the Medicine and Health Sciences Commons

Downloaded from
Mujwara, Deo and Kimmel, April D., "Offering the Choice of Self-Administered Oral HIV Testing (CHIVST)
among Long-distance Truck Drivers in Kenya: A Trial-based Cost-effectiveness Analysis" (2020). Graduate
Research Posters. Poster 93.
https://scholarscompass.vcu.edu/gradposters/93

This Poster is brought to you for free and open access by the Graduate School at VCU Scholars Compass. It has
been accepted for inclusion in Graduate Research Posters by an authorized administrator of VCU Scholars
Compass. For more information, please contact libcompass@vcu.edu.

Offering
the Choice
of Self-Administered
Oral HIV Testing
Long-distance Truck Drivers in Kenya:
Geographic
Barriers
to Comprehensive,
Coordinated
Care in among
the US South
Kimmel AD, et al.
A Trial-based Cost-effectiveness Analysis
Deo Mujwara
and April D.
Kimmel, PhD of
Department
of Health Behavior
and Policy
Virginia Commonwealth University School
of Medicine,
Department
Health Behavior
and Policy
Choice of self-testing: Costs more, but cost-effective

Awareness of HIV status is critical for achieving UNAIDS targets, particularly
sub-populations at high risk of acquiring and transmitting HIV who may
require targeted, resource-intensive strategies for HIV test uptake.

LDTDs offered CHIVST were 23% (95% CI 11 – 37%) more likely to uptake any
HIV test vs those offered provider-administered testing. This translated to over
six LDTDs offered CHIVST for each additional test uptake (Table 2).

Long distance truck drivers (LDTDs) are a high-HIV-risk sub-population
facing unique healthcare barriers due to continuous travel and irregular
schedules. A novel intervention—the choice to HIV self-test (CHIVST) at a
roadside clinic—increased test uptake for Kenyan LDTDs (Kelvin AIDS Care
2018). We conducted a trial-based cost-effectiveness analysis of CHIVST vs
provider testing to inform decision making in resource-limited settings.

CHIVST is cost-effective at willingness to pay threshold of I$97 for each
additional test uptake. This cost-effectiveness ratio falls below 3x Kenya’s
2017 GDP/capita ((I$97 < I$9,774, Table 2), a commonly used willingness to
pay threshold for assessing cost-effectiveness in low-income settings. Per
patient costs across cost domains ranged from I$0.11 (equipment) to I$13.17
(HIV self-test kit), with mean total per patient costs for CHIVST >2x for SOC
(Table 1).

Estimating cost-effectiveness
Effectiveness data came from a randomized controlled trial of clinic- or
home-based self-administered oral HIV testing (n=150) vs provideradministered testing (standard of care, n=155) for LDTDs at roadside clinics
in Kenya. Economic cost data were from the literature, reflected a societal
perspective, and were reported in 2017 international dollars (2017 I$).
Generalized Poisson and linear gamma regression models were used to
estimate effectiveness and incremental costs. Incremental effectiveness was
the reciprocal of the difference in absolute risk of HIV testing uptake across
trial arms and expressed as the number needed to treat, or the number
offered CHIVST for an additional HIV test uptake. We reported incremental
cost-effectiveness ratios, with 95% CIs calculated using Fieller’s theorem.
Deterministic sensitivity analysis identified key cost drivers of variation in
the cost-effectiveness ratio. Non-parametric bootstrapping was used to
estimate the probability of cost-effectiveness at a given willingness-to-pay
threshold.

Table 2. Incremental effectiveness, costs, and cost-effectiveness
Outcome

Base case estimate

95% CI

Number needed to treat (NNT)

6.25

[5.00 – 8.33]

Incremental cost (2017 I$)

15.55

[12.72 – 18.38]

Cost-effectiveness ratio (2017 I$)

97.18

[65.74 – 120.98]

Self-test kits and patient time are the main cost drivers of cost-effectiveness
(Figure 1). The probability that CHIVST is cost-effective approaches one at a
willingness-to-pay threshold of I$140 (Figure 2), which is substantially lower
than the GDP/capita of Kenya in 2017.

Choice of self-testing is an efficient use of resources
Offering the choice of HIV self-testing to long-distance truck drivers at
roadside clinics is a highly efficient use of resources. Our findings add to
growing evidence on the cost-effectiveness of HIV self-testing among highrisk populations in resource-limited settings. Future work should consider
long-term health and economic outcomes, which were not captured in this
study’s analytic time horizon, as well as the application of self-testing options
in other high-risk populations.
Acknowledgements:
Supported in part by the International Initiative for Impact Evaluation (3IE # TW2.2.06) and Virginia Commonwealth
University. Additional support comes from the National Institutes of Health’s National Institute of Allergy and
Infectious Diseases (NIAID), the Eunice Kennedy Shriver National Institute of Child Health & Human Development
(NICHD), the National Cancer Institute (NCI), the National Institute on Drug Abuse (NIDA), the National Heart, Lung,
and Blood Institute (NHLBI), the National Institute on Alcohol Abuse and Alcoholism (NIAAA), the National Institute of
Diabetes and Digestive and Kidney Diseases (NIDDK), the Fogarty International Center (FIC), the National Library of
Medicine (NLM), and the Office of the Director (OD) under Award Number U01AI096299 (Central Africa-IeDEA).

Figure 1. Cost of HIV self-test kit is the primary driver of variation in the ICER
HIV self-test kit

Table 1. Mean per patient costs for CHIVST vs standard of care (2017 I$)
Mean per patient costs [95% CI]
Cost domain
CHIVST
SOC
P-value
13.17 [11.52 – 14.81]
0.00 [0.00 – 0.00]
<0.001
HIV test kit
Medical supplies 0.28 [0.26 – 0.31]
0.25 [0.23 – 0.28]
0.090
Labor
Nurses
2.60 [2.43 – 2.78]
1.87 [1.68 – 2.06]
<0.001
Other
0.94 [0.87 – 1.02]
0.84 [0.76 – 0.93]
0.090
Health facility
1.57 [1.44 – 1.71]
1.41 [1.27 – 1.55]
0.090
Equipment
0.11 [0.43 – 0.17]
0.00 [0.00 – 0.00]
<0.001
Overhead
4.07 [3.79 – 4.35]
3.47 [3.12 – 3.82]
0.009
3.79 [3.55 – 4.04]
2.62 [2.35 – 2.88]
<0.001
Patient time
10.47 [9.43– 11.52] <0.001
Per patient cost 26.56 [24.31 – 28.80]

Offering selfadministered oral
HIV-testing is a costeffective strategy to
increase HIV test
uptake for longdistance truck drivers

Figure 2. The probability CHIST is cost-effective is high at low WTP thresholds
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